Background {#Sec1}
==========

The aetiological association between genes and environmental factors in the development of rheumatoid arthritis (RA) is well-established today, with specific *HLA-DRB1* alleles, termed the shared epitope (SE), as the major genetic contributor \[[@CR1]\], and smoking as the main environmental risk factor \[[@CR2]\]. Moreover, there is a strong biological interaction between smoking and SE, specifically in anti-citrullinated protein antibody (ACPA)-positive RA \[[@CR3]\]. Importantly though, current knowledge does not explain the whole risk of developing RA and there has been an extensive search for additional environmental factors predisposing individuals to RA.

The link between an infectious agent and the development of RA has long been discussed, and three decades ago researchers reported that patients with RA have higher frequency and increased antibody titres against Epstein-Barr virus (EBV) compared to controls \[[@CR4], [@CR5]\]. Since then, a number of studies have addressed the possible role of viral infections in the aetiopathogenesis of RA. In addition to EBV \[[@CR6]\], other viruses have been implicated, including human parvovirus B19 (B19) \[[@CR7], [@CR8]\], and cytomegalovirus (CMV) \[[@CR9]\].

EBV and CMV belong to the human herpes virus family. Primary infection is often asymptomatic, but may cause severe morbidity, even mortality, in immunocompromised patients. Infection by parvovirus B19 may cause erythema infectiosum (fifth disease), predominantly affecting children. In adults, B19 often causes self-limiting acute symmetric polyarthritis \[[@CR10]\], with symptoms disappearing within a few weeks, although arthralgia may persist for months, even years, in about 20%, usually women \[[@CR11]\], suggesting that polyarthritis caused by B19 may progress to RA.

Whereas a number of serological studies have identified higher antibody levels against these viruses and/or increased antibody frequency in RA compared to controls \[[@CR4], [@CR5], [@CR7], [@CR12]\], other studies have not replicated these findings \[[@CR13]--[@CR15]\]. In addition to serological evidence, viral DNA has been detected in the synovium and bone marrow of patients with RA \[[@CR7], [@CR12]--[@CR23]\], and studies also report on the presence of viral proteins in the joints of patients with RA \[[@CR7], [@CR16], [@CR17]\]. However, other studies have had conflicting results \[[@CR24]--[@CR26]\].

Most studies performed to date, on the association between viral infections and RA development, have used small cohorts and often lack well-matched control groups. With this in mind, it seems difficult to draw any conclusions from the current literature, which presents contradictory results. Furthermore, studies during the past decade have highlighted the importance of autoimmunity to citrullinated proteins, when investigating genetic and environmental risk factors for RA, and such studies have not been conducted when it comes to viral infections.

Using the large population-based Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) case-control study, we had a unique opportunity to analyse anti-viral antibody levels in relation to RA, autoantibodies, genetic risk factors, smoking habits and clinical parameters. Hence, in the present study we have investigated the associations of EBV, B19 and CMV viruses with ACPA-positive and ACPA-negative disease, in relation to SE, smoking status, disease activity score in 28 joints (DAS28) and C-reactive protein (CRP) levels by measuring anti-viral IgG in sera from 990 patients with RA (cases) and 700 matched controls.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This study is based on 990 patients with RA and 700 age-matched, gender-matched and residential-area-matched controls from the EIRA cohort. Incident cases were diagnosed according to the 1987 American College of Rheumatology criteria \[[@CR27]\]. Participants donated blood at inclusion (at the time of diagnosis of RA) and filled in a questionnaire on lifestyle/environment. Patients had not been treated with disease-modifying anti-rheumatic drugs (DMARDs) prior to this time point. Details of EIRA are described elsewhere \[[@CR2]\]. Information on ACPA, smoking, genetics and clinical data were retrieved from the EIRA database, and has described before \[[@CR2], [@CR3], [@CR28], [@CR29]\]. Briefly, EIRA participants were categorised as ever-smokers (current and former smokers) or never-smokers, and genotyped for *HLA-DRB1* alleles (*HLA-DRB1*\*01 (except *DRB1*\*0103), \*04 and \*10 were classified as SE). ACPA was measured as anti-CCP2 IgG using Immunoscan CCPlus® (Euro-Diagnostica AB, Malmö, Sweden). Clinical data (DAS28 and CRP) were captured by linking EIRA with the Swedish rheumatology register, where clinical data are registered as part of standard care \[[@CR29]\]. The study population is described in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of EIRA RA cases and controlsRA cases (n = 990)Controls (n = 700)Age, years, mean (SD)50.5 (12.7)51.5 (11.9)Gender, female/male (% female)700/290 (71)500/200 (71)ACPA positive (%)601 (61)N/AIgM RF positive (%)653 (66)N/ADAS28, median (IQR)5.07 (4.08-5.91)N/ACRP, mg/l, median (IQR)16.0 (8.0-31.0)N/ASmoking status, ever^a^ (%)558 (56)355 (51)*HLA-DRB1* SE positive^b^ (%)711 (72)342 (49)^a^Former and current cigarette smokers.^b^Carriers of one or two *HLA-DRB1* SE alleles*ACPA* anti-citrullinated protein antibody, *RF* rheumatoid factor, *CRP* C-reactive protein, *DAS28* disease activity score in 28 joints, *IQR* interquartile range, *N/A* not applicable, *RA* rheumatoid arthritis, *SD* standard deviation, *SE* shared epitope

Detection of anti-viral IgG in serum {#Sec4}
------------------------------------

Anti-CMV IgG was analysed using a chemiluminescent microparticle immunoassay (Architect, Abbott Diagnostics, Wiesbaden, Germany). Antibodies against EBV viral capsid antigen, and parvovirus B19, were measured by enzyme-linked immunosorbent assay (ELISA) kits (Biorad, Dreieich, Germany, and Biotrin International, Dublin, Ireland, respectively). All immunoassays were performed and interpreted according to the manufacturers\' instructions, including setting of the cutoff values. The cutoff for positivity was ≥ 6.0 arbitrary units (AU)/ml for anti-CMV IgG, and \> 1.0 index value for both anti-EBV IgG and anti-B19 IgG. Anti-CMV and anti-EBV antibodies were analysed in 987 patients with RA and 700 controls, while anti-B19 antibodies were analysed in 979 patients with RA and 692 controls.

Detection of rheumatoid factor in serum {#Sec5}
---------------------------------------

Levels of IgM rheumatoid factor (RF) were analysed in all 990 patients with RA from the EIRA cohort, using the EliA immunoassay on the Phadia 2500 system (Phadia GmbH, Freiburg, Germany), according to the manufacturer\'s instructions.

Statistical analysis {#Sec6}
--------------------

Statistical differences in anti-viral antibody frequencies between different RA subsets and controls were determined using Fisher's exact test and the chi-squared test. The Mann-Whitney *U* test was used to examine anti-viral IgG levels. Linear regression was used to determine the correlation between anti-viral antibody levels and DAS28/CRP, age and RF. Unconditional logistic regression was used to calculate odds ratios (OR) with 95% confidence intervals (CI) for the association between high/low anti-viral antibody levels and different RA subsets. Quartiles of anti-viral antibody levels were used, and the highest quartile (25%) was compared to the lower three quartiles (75%). Cutoffs were based on anti-viral IgG levels among controls. Analyses were adjusted for age, gender and residential area. The attributable proportion (AP) due to additive interaction was evaluated between smoking, SE and virus exposure, regarding the risk of ACPA-positive RA, with 95% CI, as previously described \[[@CR30]\]. Analyses were performed using GraphPad PRISM 6 and SAS version 9.3. *P* values \<0.05 were considered statistically significant.

Results {#Sec7}
=======

Prevalence of anti-viral antibodies in EIRA {#Sec8}
-------------------------------------------

In order to determine whether infection with the common viruses CMV, EBV and parvovirus B19 was more frequent in patients with RA than in non-RA subjects, we measured anti-viral antibodies in serum from 990 patients with RA and 700 matched controls, using presence of anti-viral antibodies as surrogate markers for viral infection. We detected high frequencies of anti-viral antibody-positive individuals in the EIRA cohort, with no statistical differences between patients with RA and controls in the prevalence of any of the viruses. The prevalence of anti-EBV IgG was 98.3% and 97.0%, in patients with RA and controls, respectively; anti-B19 IgG was detected in 75.8% of patients with RA and in 72.8% of controls; and anti-CMV IgG was found in 72.2% of patients with RA and in 75.9% of controls. When dividing patients with RA into ACPA-positive and ACPA-negative subsets, there was a marginally higher frequency of anti-B19 IgG-positive individuals in ACPA-positive RA compared to controls (77.6% versus 72.8%, respectively, *p* = 0.0466) (Fig. [1a](#Fig1){ref-type="fig"}). When looking at the combination of anti-EBV, anti-B19 and anti-CMV antibodies we found no major differences between patients with RA and controls, or between patients with ACPA-positive and ACPA-negative RA. Triple positivity was most common (55--57%), followed by double positivity (34--36%), while only 8--11% were single positive, with EBV being the most common reactivity. Less than 1% was triple negative (Additional file [1](#MOESM1){ref-type="media"}: Figure S1).Fig. 1Anti-viral antibody levels in the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study: patients with rheumatoid arthritis (RA) and controls. Anti-Epstein-Barr virus (EBV) IgG (left panel), anti-B19 IgG (middle panel) and anti-cytomegalovirus (CMV) IgG (right panel) levels are shown for all study subjects (**a**) or only for anti-viral antibody-positive study subjects (**b**). The red lines indicate median antibody levels. The prevalence (%) of anti-viral antibody-positive individuals in each subset is presented below the graphs in **a**. *P* values \<0.05 were considered statistically significant. \*Statistical difference in antibody frequency between patients with ACPA-positive RA and controls (*p* = 0.0466) (**a**) (middle panel)

Anti-viral antibody levels in the EIRA cohort {#Sec9}
---------------------------------------------

Since we found no major differences in anti-viral antibody prevalence between groups, we proceeded to compare antibody levels. When including all individuals in these analyses, irrespective of anti-viral antibody status, only anti-EBV IgG levels differed significantly, with lower antibody levels detected in patients with RA compared to controls (*p* = 0.0155), specifically in ACPA-positive RA (*p* = 0.0112) (Fig. [1a](#Fig1){ref-type="fig"}). When focusing the analysis on anti-viral antibody-positive individuals only, both anti-EBV and anti-B19 IgG levels were significantly lower in ACPA-positive RA compared to controls (*p* = 0.0026 and *p* = 0.0086, respectively) (Fig. [1b](#Fig1){ref-type="fig"}). Anti-B19 antibody levels were also significantly lower in ACPA-positive RA compared to ACPA-negative RA (*p* = 0.0082). In order to address the possibility that RF, which is more commonly detected in ACPA-positive RA than in ACPA-negative RA, was interfering with the detection of anti-viral antibodies and thereby caused lower anti-EBV and anti-B19 IgG levels in the ACPA-positive subset, we analysed the levels of IgM RF in relation to all three anti-viral antibody levels in all EIRA RA samples. We found no correlation, hence conclude that RF did not affect anti-viral antibody levels (Additional file [2](#MOESM2){ref-type="media"}: Figure S2).

Inverse association between high anti-viral antibody levels and RA {#Sec10}
------------------------------------------------------------------

Due to the high frequency of seropositivity for all three anti-viral antibodies, further analyses based on seropositivity versus seronegativity would be non-informative. Instead, we analysed quartiles of anti-viral antibody levels and compared the highest quartile (25%) with the lower three quartiles (75%), in order to investigate whether high levels of anti-viral antibodies were associated with RA and/or different subsets of RA. Logistic regression analysis revealed that high levels of anti-viral antibodies did not increase the risk of RA. If anything, the opposite was observed. High levels of anti-viral antibodies were inversely associated with RA, with statistically significant odds ratios for both anti-EBV (OR = 0.7; 95% CI 0.5--0.9) and anti-B19 IgG (OR = 0.7; 95% CI 0.6--0.9). The significant associations were only confined to the ACPA-positive subset, with odds ratios of 0.6 (95% CI 0.5--0.8) for both EBV and B19 (Table [2](#Tab2){ref-type="table"}). There was no association between ACPA-negative disease and any of the anti-viral antibodies investigated.Table 2Association between high levels of anti-viral antibodies and RA in subgroups of patients, divided based on the presence/absence of ACPAGroupsVirusCases (%)Controls (%)OR (95% CI)^a^All RAEBV low^b^805 (81)525 (75)1.0 refAll RAEBV high^c^185 (19)175 (25)*0.7 (0.5--0.9)*ACPA- RAEBV low307 (79)525 (75)1.0 refACPA- RAEBV high82 (21)175 (25)0.8 (0.6--1.1)ACPA+ RAEBV low498 (83)525 (75)1.0 refACPA+ RAEBV high103 (17)175 (25)*0.6 (0.5--0.8)*All RAB19 low796 (80)525 (75)1.0 refAll RAB19 high194 (20)175 (25)*0.7 (0.6--0.9)*ACPA- RAB19 low296 (76)525 (75)1.0 refACPA- RAB19 high93 (24)175 (25)0.9 (0.7--1.2)ACPA+ RAB19 low500 (83)525 (75)1.0 refACPA+ RAB19 high101 (17)175 (25)*0.6 (0.5--0.8)*All RACMV low753 (76)524 (75)1.0 refAll RACMV high234 (24)175 (25)0.9 (0.7--1.2)ACPA- RACMV low296 (76)524 (75)1.0 refACPA- RACMV high91 (24)175 (25)1.0 (0.8--1.3)ACPA+ RACMV low457 (76)524 (75)1.0 refACPA+ RACMV high143 (24)175 (25)0.9 (0.7--1.2)*RA* rheumatoid arthritis, *ACPA* anti-citrullinated protein antibody, *CI* confidence interval, *EBV* Epstein-Barr virus, *CMV* cytomegalovirus, *ref* reference^a^Odds ratios (OR) were adjusted for age, gender and residential area. Significant ORs are shown in italics^b^Low indicates lower three quartiles of antibody titres (75% lowest)^c^High indicates highest quartile of antibody titres (25% highest)

In addition, we analysed different combinations of high or low anti-viral antibody levels in RA (ACPA-positive and ACPA-negative) and controls. In line with the data presented in Table [2](#Tab2){ref-type="table"}, this analysis clearly illustrated that patients with ACPA-positive RA differed from controls, and from patients with ACPA-negative disease (Additional file [3](#MOESM3){ref-type="media"}: Figure S3). Having low antibody levels to all viruses was the most common combination (44% in controls; 46% in ACPA-negative RA; 53% in ACPA-positive RA), followed by low antibody levels to two viruses (i.e. high antibody levels to one virus - B19 in controls and ACPA-negative RA, and CMV in ACPA-positive RA).

Anti-viral antibodies in relation to smoking and SE in ACPA-positive RA {#Sec11}
-----------------------------------------------------------------------

We next analysed the associations and interactions of anti-viral antibody levels with two well-established risk factors for ACPA-positive RA, the *HLA-DRB1* SE alleles and smoking. Also here, we compared the highest quartile (25%) of antibody levels with the lower three quartiles (75%). Since high levels of anti-viral antibodies seemed to be protective against ACPA-positive RA, while presence of smoking and SE are well-known risk factors, the referent groups in these analyses were negative for SE and/or smoking, but positive for the highest quartile of anti-viral antibody levels. There was no significant association of low anti-EBV or low anti-CMV antibody levels with ACPA-positive RA in the absence of smoking (Table [3](#Tab3){ref-type="table"}). However, low levels of anti-B19 antibodies were - independent of smoking - associated with ACPA-positive RA (OR = 2.3; 95% CI 1.3--4.1). In the presence of smoking, the odds ratio for this specific association increased to 4.4 (95% CI 2.5--7.7). No signs of interactions, calculated as the attributable proportion (AP) due to additive interaction, were identified between smoking and low levels of any of the anti-viral antibodies.Table 3Association and additive interaction between smoking and anti-viral antibodies in ACPA-positive RAFactorsCases (%)Controls (%)OR (95% CI)^a^SmokingEBV-high^b^20 (3.82)55 (9.06)1.0 ref-low^c^126 (24.09)197 (32.45)1.6 (0.9--2.8)+high73 (13.96)96 (15.82)*2.1 (1.1--3.9)*+low304 (58.13)259 (42.67)*3.2 (1.9 − 5.6)*AP (95% CI)0.2 (-0.2--0.5)SmokingB19-high18 (3.44)61 (10.05)1.0 ref-low128 (24.47)191 (31.47)*2.3 (1.3--4.1)*+high69 (13.19)89 (14.66)*2.8 (1.5--5.2)*+low308 (58.89)266 (43.82)*4.4 (2.5--7.7)*AP (95% CI)0.1 (-0.3--0.4)SmokingCMV-high24 (4.59)51 (8.40)1.0 ref.-low122 (23.33)201 (33.11)1.4 (0.8--2.3)+high109 (20.84)100 (16.47)*2.6 (1.5--4.6)*+low268 (51.24)255 (42.01)*2.5 (1.5--4.3)*AP (95% CI)-0.2 (-0.6--0.3)*ACPA* anti-citrullinated protein antibody, *RA* rheumatoid arthritis, *AP* attributable proportion due to additive interaction, *CI* confidence interval, *EBV* Epstein-Barr virus, *CMV* cytomegalovirus, *ref* reference^a^Odds ratios (OR) were adjusted for age, gender and residential area. Significant ORs are shown in italics^b^High indicates the highest quartile of antibody titres (25% highest)^c^Low indicates the lower three quartiles of antibody titres (75% lowest)

Analyses of *HLA-DRB1* SE in the context of anti-viral antibodies identified significant interaction between SE and low levels of both anti-EBV and anti-B19 antibodies, with an AP due to the interaction of 0.5 (95% CI 0.3--0.7) and 0.3 (95% CI 0.1--0.5), respectively (Table [4](#Tab4){ref-type="table"}). Low levels of anti-B19 antibodies were also independently (of *HLA-DRB1* SE) associated with ACPA-positive RA. Low anti-CMV antibody levels were not associated with ACPA-positive RA and there was no interaction with SE.Table 4Association and additive interaction between *HLA-DRB1* SE alleles and anti-viral antibodies in ACPA-positive RAFactorsCases (%)Controls (%)OR (95% CI)^a^*HLA-DRB1* SEEBV-high^b^17 (2.83)76 (11.00)1.0 ref-low^c^76 (12.67)273 (39.51)1.2 (0.6--2.1)+high85 (14.17)97 (14.03)*3.9 (2.1--7.2)*+low422 (70.33)245 (35.46)*7.9 (4.5--13.8)*AP (95% CI)*0.5 (0.3--0.7)HLA-DRB1* SEB19-high9 (1.50)77 (11.14)1.0 ref-low84 (14.00)272 (39.36)*2.7 (1.3--5.7)*+high92 (15.33)96 (13.89)*8.8 (4.1--18.8)*+low415 (69.17)246 (35.60)*15.7 (7.7--32.2)*AP (95% CI)*0.3 (0.1--0.5)HLA-DRB1* SECMV-high17 (2.84)88 (12.75)1.0 ref-low76 (12.69)261 (37.83)1.5 (0.9--2.8)+high125 (20.87)86 (12.46)*8.2 (4.5--15.0)*+low381 (63.60)255 (36.96)*8.4 (4.8--14.6)*AP (95% CI)-0.05 (-0.4--0.3)*ACPA* anti-citrullinated protein antibody, *RA* rheumatoid arthritis, *AP* attributable proportion due to additive interaction, *CI* confidence interval, *EBV* Epstein-Barr virus, *CMV* cytomegalovirus, *ref* reference^a^Odds ratios (OR) were adjusted for age, gender, and residential area. Significant ORs are shown in italics^b^High indicates highest quartile of antibody titres (25% highest)^c^Low indicates lower three quartiles of antibody titres (75% lowest)

In order to better clarify the role of SE in relation to lower anti-viral antibody levels, as seen in ACPA-positive RA, we also compared anti-EBV and anti-B19 IgG levels in SE-positive and SE-negative subsets of patients with ACPA-positive RA, patients with ACPA-negative RA and controls. Within each subgroup, anti-viral antibody levels did not differ significantly based on SE status (Fig. [2](#Fig2){ref-type="fig"}), hence SE does not seem to directly influence these specific anti-viral antibody levels. Within the SE-positive subset, anti-B19 and anti-EBV IgG levels were significantly lower in RA and ACPA-positive RA (and also in ACPA-negative RA for EBV) compared to controls, while anti-B19 IgG levels were significantly lower in ACPA-positive RA compared to ACPA-negative RA, when comparisons were made within the SE-negative subset.Fig. 2Anti-viral antibody levels in patients with rheumatoid arthritis (RA) from the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study and in controls, in relation to *HLA-DRB1* shared epitope (SE) alleles. Anti-Epstein-Barr virus (EBV) IgG (**a**) and anti-B19 IgG (**b**) levels were compared between SE-positive and SE-negative: controls, patients with RA, anti-citrullinated protein antibody (ACPA)-positive patients with RA and ACPA-negative patients with RA, and were compared in different subsets of patients with RA and in controls in the presence or absence of the SE. The red lines indicate median antibody levels. *P* values \<0.05 were considered statistically significant

Anti-viral antibody levels in relation to age, inflammation and disease activity {#Sec12}
--------------------------------------------------------------------------------

Finally, we examined whether there was correlation between anti-viral antibody levels and baseline clinical characteristics, specifically inflammation (measured as CRP) and disease activity (measured as the DAS28), and we found no correlation for any virus, in any subset of RA (Additional file [4](#MOESM4){ref-type="media"}: Figure S4). Age, on the other hand, correlated weakly with lower anti-B19 IgG levels and higher anti-CMV IgG levels, in both patients with RA and controls (Additional file [5](#MOESM5){ref-type="media"}: Figure S5).

Discussion {#Sec13}
==========

In this study, we have investigated a possible association between infection by common viruses and the development of RA. To our knowledge, this is the largest epidemiological study conducted to date, where the prevalence of anti-EBV, anti-CMV and anti-B19 antibodies was investigated in a population-based RA case-control cohort. For the first time, these viruses have been examined in the context of ACPA, and genetic (*HLA-DRB1* SE) and environmental (smoking) risk factors, which today are known to contribute to disease development only in subsets of RA.

The frequencies of anti-viral antibodies were high in EIRA, and rather similar when comparing patients with ACPA-positive RA, patients with ACPA-negative RA and controls. We detected no significant differences in anti-EBV or anti-CMV IgG, while the prevalence of anti-B19 antibody-positive individuals was somewhat higher in ACPA-positive RA compared to controls. Interestingly, we found significant associations between low anti-EBV and low anti-B19 IgG levels and ACPA-positive RA. Our data are thus in agreement with a number of previous reports \[[@CR12], [@CR14], [@CR15]\], yet contradictory to others \[[@CR4], [@CR5], [@CR13]\]. Explanations for these discrepant results could be: (1) differences in the number of study participants, where low numbers could result in insufficient statistical power and skewed data; (2) differences in storage and processing of biological material, which may affect the antibody detection assay; (3) differences in study populations, in age, ethnicity and/or disease duration; and/or (4) differences in anti-rheumatic treatments, where immune modulatory and anti-inflammatory treatments could have negative effects on antibody titres, by altering the activity of plasma cells \[[@CR31], [@CR32]\].

We have used the well-characterized EIRA cohort, with 990 patients with early RA and 700 matched controls in our study, providing proper controls and high statistical power. In addition, all patients in the EIRA cohort were DMARD-naïve, and serum samples were stored at minus 80 °C until examined, minimizing potential negative effects on antibody titres. We have measured anti-viral IgG levels, and used these as surrogate markers for viral infections. Others have focused on the presence of viral DNA \[[@CR7], [@CR13], [@CR17]--[@CR19], [@CR21], [@CR22]\] or viral proteins \[[@CR7], [@CR16], [@CR20], [@CR24]\] instead, or they have used other types of assays to detect anti-viral antibodies \[[@CR4], [@CR5], [@CR12], [@CR14], [@CR21]\].

The observation of lower anti-EBV and anti-B19 IgG levels in ACPA-positive RA could point towards an inability to mount a proper antibody response against pathogens in this subset of RA. However, generally lower antibody response to pathogens is, to our knowledge, not a specific feature of ACPA-positive RA. On the contrary, we have recently shown elevated antibody levels to the oral pathogen *Porphyromonas gingivalis* in patients with ACPA-positive RA, compared to patients with ACPA-negative RA and controls \[[@CR33]\]. The use of corticosteroids could have a negative effect on serum IgG levels \[[@CR31]\], and although our study only included newly diagnosed DMARD-naïve patients, we have no information on the potential use of corticosteroids before RA diagnosis. Approximately 30% of all patients in the EIRA cohort are put on prednisolone when they are diagnosed \[[@CR29]\]. Importantly though, ACPA-positive and ACPA-negative patients are clinically very similar at this time point, and prednisolone was not more frequently administered to ACPA-positive patients compared to ACPA-negative in the EIRA cohort (personal communication, Dr Saedis Seavarsdottir). Hence, we find it unlikely that the potential use of cortisone prior to this time point would differ between ACPA-positive and ACPA-negative patients, suggesting that corticosteroids could not explain the lower anti-EBV and anti-B19 IgG levels detected in the ACPA-positive subset in our study.

Low anti-viral IgG levels could reflect low viral replication, and low viral load \[[@CR34]\]. On the other hand, one could speculate that low anti-viral antibody levels may instead indicate an insufficient anti-viral antibody response, with poor viral control, allowing for increased viral replication, resulting in higher viral load \[[@CR35]\]. With this interpretation of data, our observation of an interaction between low anti-EBV and low anti-B19 antibody levels and *HLA-DRB1* SE would support a number of other studies that have linked EBV and B19 to SE and RA. Balandraud and colleagues, for example, have shown that patients with RA expressing *HLA-DRB1\**0404 (i.e. SE positive) have higher EBV viral DNA load in peripheral blood mononuclear cells (PBMCs) than patients expressing *HLA-DRB1\**07 (i.e. SE negative) \[[@CR35]\], although the difference was not statistically significant (*p* = 0.08). In another study, the frequencies of *HLA-DRB1* (\*01, \*04 and \*07) alleles were shown to be significantly higher in individuals with symptomatic acute B19 infection than in healthy controls \[[@CR36]\]. Moreover, Saal et al. showed that SE-positive individuals with EBV DNA detected in the synovial membrane had a higher risk of developing RA than individuals who were negative for one or both of these variables \[[@CR19]\], and Chen et al. demonstrated synergistic effects between *HLA-DRB1*\*04 and parvovirus B19 infection in RA susceptibility \[[@CR12]\]. Collectively, these reports suggest that EBV and B19 may constitute environmental triggers for the development of RA in genetically predisposed individuals.

A number of studies have also suggested the possibility of autoimmunity arising as a result of molecular mimicry after EBV or B19 infection \[[@CR37]--[@CR39]\]. Anti-VP1 IgG (antibodies directed against B19 structural protein) for example, have been shown to cross-react with type II collagen, a major component in hyaline cartilage, and a target of autoantibodies in RA \[[@CR40]\]. Moreover, antibodies to citrullinated EBV peptides have been described in RA \[[@CR41]--[@CR44]\], and Rossi et al. showed that ACPA from patients with RA have higher affinity for citrullinated autoantigens (in this case histone citrullinated peptide 1), than for citrullinated peptides derived from EBV proteins (i.e. exogenous antigens) \[[@CR45]\], suggesting that these antibodies are initially produced against exogenous antigen and later selected and expanded by autoantigens.

Recent studies have also shown that EBV can persist in self-reactive memory B cells, thereby favouring the survival of pathogenic autoreactive B cells \[[@CR46], [@CR47]\]. In addition, macrophages and lymphocytes infected by B19 provide another possible mechanism by which viruses could contribute to autoimmunity, through the continuous secretion of pro-inflammatory cytokines resulting in polyclonal B cell activation and proliferation of synovial B cells \[[@CR7], [@CR48]--[@CR50]\].

A weakness of our study is that we have only analysed anti-viral IgG levels, which most probably reflect infections occurring in childhood. We have not analysed anti-viral IgM or presence of viral DNA, which could have given us information about acute infections/re-activation of the viruses. Moreover, whether low anti-viral antibody levels reflect low viral load, or the opposite, high viral load, is not clear, and may differ from virus to virus. In order to dissect the role of common viruses in RA aetiology in detail, and the relationship between viral load and the anti-viral immune response, in the context of SE and ACPA, longitudinal studies should be performed, in which viral DNA and anti-viral IgM is measured in addition to anti-viral IgG.

Conclusion {#Sec14}
==========

In conclusion, our study demonstrates an inverse/negative association between high anti-EBV and high anti-B19 IgG levels and the risk of developing ACPA-positive RA. Moreover, we detected significant associations between low anti-B19 and low anti-EBV IgG levels and ACPA-positive RA, especially in the context of *HLA-DRB1* SE. Hence, our data imply that a strong immune response against parvovirus and EBV virus (which historically could have been implicated in arthritis development) may in fact be protective in a pathogenically well-defined subset of patients with RA.

Additional files
================

 {#Sec15}

Additional file 1: Figure S1.Prevalence of being positive for different combinations of anti-viral antibodies in RA, ACPA-positive RA, ACPA-negative RA and in controls. Seropositivity for one, two, three or no anti-viral antibodies are shown in **A**. Seropositivity for different combinations of anti-EBV, anti-B19 and anti-CMV IgG are shown in **B**. (EPS 111 kb) Additional file 2: Figure S2.Correlation between anti-EBV (left panel), anti-B19 (middle panel) and anti-CMV (right panel) IgG levels and IgM rheumatoid factor (RF) levels in all patients with RA (upper row), ACPA-positive patients with RA (middle row) and ACPA-negative patients with RA (lower row). (EPS 1873 kb) Additional file 3: Figure S3.Prevalence of having different combinations of high and low anti-EBV, anti-B19 and anti-CMV antibody levels in RA, ACPA-positive RA, ACPA-negative RA, and in controls. "High" indicates the highest quartile of antibody titres (25% highest). "Low" indicates the lower three quartiles of antibody titres (75% lowest). (EPS 89 kb) Additional file 4: Figure S4.Correlations between anti-EBV (left panel), anti-B19 (middle panel), anti-CMV (right panel) IgG levels and C-reactive protein (CPR) levels (**A**) and disease activity score (DAS28) (**B**) in all patients with RA (upper row), in ACPA-positive patients with RA (middle row) and in ACPA-negative patients with RA (lower row). (EPS 1848 kb) Additional file 5: Figure S5.Correlations between anti-EBV (left panel), anti-B19 (middle panel), anti-CMV (right panel) IgG levels and age in patients with RA (**A**) and in controls (**B**). (EPS 1320 kb)

ACPA

:   Anti-citrullinated protein antibody

AP

:   Attributable proportion

AU

:   Arbitrary units

B19

:   Human parvovirus B19

CI

:   Confidence intervals

CMV

:   Cytomegalovirus

CRP

:   C-reactive protein

DAS28

:   Disease activity score in 28 joints

DMARD

:   Disease-modifying drug

EBV

:   Epstein-Barr virus

EIRA

:   Swedish Epidemiological Investigation of Rheumatoid Arthritis

ELISA

:   Enzyme-linked immunosorbent assay

IQR

:   Interquartile range

N/A

:   Not applicable

OR

:   Odds ratio

PBMC

:   Peripheral blood mononuclear cells

RA

:   Rheumatoid arthritis

RF

:   Rheumatoid factor

SD

:   Standard deviation

SE

:   Shared epitope

Natalia Sherina and Hulda S. Hreggvidsdottir are contributed equally.

Natalia Sherina and Hulda S. Hreggvidsdottir are share first authorship.

**Electronic supplementary material**

The online version of this article (doi:10.1186/s13075-017-1423-9) contains supplementary material, which is available to authorized users.

We thank patients and controls, research nurses and clinicians, and the EIRA study group for their important contributions; Professor Lars Klareskog, for support and scientific discussions, and for establishing the EIRA cohort together with Professor Lars Alfredsson; scientists previously involved in collecting data for the EIRA database, specifically: Associate Professor Leonid Padyukov, Dr Patrik Stolt, Professor Johan Askling, Dr Saedis Saevarsdottir, and Dr Helga Westerlind; Dr Martina Johannesson, for support in supervising; and Professor Tomas Olsson and Professor Kristina Broliden, for scientific input and discussions.

Funding {#FPar1}
=======

This study was supported by grants from the Swedish Research Council, the EU-funded FP7 project TRIGGER (FP7-Health-2013-306029), and the EU-funded ITN project RAPID (290246).

Availability of data and materials {#FPar2}
==================================

The dataset generated during the present study are available from the corresponding author on reasonable request.

NS performed most data analysis, and produced all figures; HH performed all anti-viral immunoassays together with LI; MH performed the IgM RF EliA immunoassay; CB had main responsibility for the statistical analysis, specifically all calculations of odds ratios and AP values, and produced the tables together with NS and HH. NS, together with KL and HH, wrote the manuscript and selected references. LA set up the EIRA cohort, and has the main responsibility for the EIRA database. KL had the main responsibility for the study, including design, experimental set-up, analyses, figures, tables, supervising and writing of the manuscript. All authors participated in critically reading and reviewing the manuscript. All authors approved the final version of the manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

Collection and handling of samples and personal data was conducted with commitment to the highest standards of data security and protection, in agreement with Swedish laws and regulations, and in accordance with the Declaration of Helsinki. In line with Swedish law, patient consent was documented in the medical records by the respective treating physician. This was done after the patient had received information about the study and after approving participation in the study (consent). Ethical permission for the study was granted from the Regional Ethical Review Board in Stockholm (Regionala Etikprövningsnämnden Stockholm).

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher\'s Note {#FPar6}
=================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
